About the
GZFD Study
You may be able to participate in the GZFD Study if you:
If you are interested in participating, the study doctor and staff will review additional eligibility criteria with you and answer any questions you may have.
Study Overview
You will take your assigned study medicine (either the investigational medicine or the placebo) as a subcutaneous injection (under the skin) once a week for 24 weeks. You will continue to take semaglutide or tirzepatide throughout the study, which will be provided as part of study participation. The study will last up to about 10 months (40 weeks), including screening and follow-up, and you will have 11 in-person visits with doctors and researchers at the study center and 1 telehealth visit.